Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Novartis Signs In-Licensing Agreement With BeiGene to Expand Tislelizumab Trials Globally

January 26th 2021

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.

FDA Approval Insights: Nivolumab/Cabozantinib in Advanced RCC

January 25th 2021

In our exclusive interview, Toni K. Choueiri, MD, provides perspective on the FDA approval of nivolumab and cabozantinib in advanced renal cell carcinoma.

Avelumab Approved in Europe for Frontline Maintenance in Metastatic Urothelial Carcinoma

January 25th 2021

January 25, 2021 - The European Commission has approved avelumab for use as a frontline maintenance option in the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who did not progress after having received platinum-based chemotherapy.

Dr. Choueiri on the FDA Approval of Nivolumab/Cabozantinib in mRCC

January 22nd 2021

Toni K. Choueiri, MD, discusses the FDA approval of nivolumab and cabozantinib in metastatic renal cell carcinoma.

FDA Approves Nivolumab Plus Cabozantinib for Advanced RCC

January 22nd 2021

January 22, 2021 - The FDA has approved the combination of nivolumab plus cabozantinib for the frontline treatment of patients with advanced renal cell carcinoma.

Lenvatinib for mRCC

January 22nd 2021

Robert Motzer, MD, describes what lenvatinib is and explains the rationale for studying its use in combination with novel therapies such as everolimus as treatment for metastatic renal cell carcinoma.

Second-Line Treatment Approaches for mRCC

January 22nd 2021

Oncologists discuss their preferences in regard to second-line therapy for metastatic renal cell carcinoma, and optimal timing for changing regimens based on responses to treatment.

FDA Grants Priority Review to Retifanlimab for Squamous Cell Carcinoma of the Anal Canal

January 21st 2021

January 21, 2021 - The FDA has granted priority review to a biologics license application for retifanlimab for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who were intolerant of or who had progressed on platinum-based chemotherapy.

Forecasting Future Advances Across Oncology

January 21st 2021

Expert discuss their expectations for research and drug development in oncology in the new year.

The Role of Cytoreductive Nephrectomy Remains Uncertain in mRCC

January 21st 2021

Justin T. Matulay, MD, discusses whether there is a role for cytoreductive nephrectomy in metastatic renal cell carcinoma, as well as key data that have helped guide this paradigm.

FDA Grants Fast Track Status to Padeliporfin ImPACT for Upper-Tract Urothelial Cancer

January 18th 2021

January 18, 2021 — The FDA has granted a fast track designation to padeliporfin Immune Photo Activated Cancer Therapy for use in the treatment of patients with low-grade and unifocal upper-tract urothelial cancer.

More Than 2 Cycles of Cisplatin Significantly Reduces Risk of Second Testicular Cancer

January 15th 2021

January 15, 2021 - The risk of a second metachronous contralateral germ cell testicular cancer is found to be significantly reduced with each additional cycle of cisplatin-based chemotherapy in patients.

mRCC: Moving to Second-Line Therapy

January 15th 2021

Factors that prompt oncologists to move to second-line therapy to treat metastatic renal cell carcinoma.

Selecting Frontline Therapy for mRCC

January 15th 2021

Variables that influence an individualized first-line treatment approach for advanced renal cell carcinoma.

Making an Impact in the Fight Against GU Cancers as Scientist, Physician, and Teacher

January 12th 2021

Long before Dean F. Bajorin, MD, would travel the world as a renowned expert in genitourinary cancers—presenting at international conferences, working with major task forces, and changing the paradigms of care for patients in every corner of the globe—he began with a decidedly shorter journey: to college.

Powles and Rini Put ctDNA Into Perspective in Urothelial Cancer

January 11th 2021

In our exclusive interview, Dr. Powles and Dr. Rini provide insight into an analysis of the phase 3 IMvigor010 study and its implications for circulating tumor DNA as a biomarker in urothelial cancer and beyond.

Dr. Hutson on Challenges With Targeted Therapy in Non-Clear Cell RCC

January 8th 2021

Thomas Hutson, DO, PharmD, discusses challenges with targeted therapy in non-clear cell renal cell carcinoma.

Dr. Campbell on the Impact of the COVID-19 Pandemic in RCC

January 8th 2021

Matthew T. Campbell, MD, MS, discusses the impact of the coronavirus disease 2019 pandemic in renal cell carcinoma.

More Innovation Is on Tap for 2021: Five Experts Describe Key Trends

January 8th 2021

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology

January 8th 2021

Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.